| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.036 | 0.2 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.2 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.2 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.18 | 0.2 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |